Crown Bioscience

📢Join industry professionals and our panel of experts at our exclusive event, Advancing Immuno-Oncology, on 25th February 2025 in London. Delve into the latest advancements in preclinical models for immunotherapies, including Antibody-Drug Conjugates (ADCs), and immune-mediated cellular therapies. Whether you are exploring novel targets, testing next-generation therapies, or navigating the complex tumor microenvironment, our speakers will break it down for you in a way that is practical and actionable. At Crown Bioscience, we are passionate about supporting the immuno-oncology community with the tools, models, and expertise needed to develop treatments that make a real difference for patients. Spaces are limited. Light lunch will be served. Reserve your seat now and be part of the conversation! ➡️https://hubs.la/Q0353pGT0 Sander Basten, PhD, Adrien Mossu, Asma Jabeen, PhD

📢Just one week to go! Don’t miss your chance to join industry leaders at our Advancing Immuno-Oncology event on 25th February 2025 in London. Get the latest insights into preclinical models for immunotherapies, including ADCs and immune-mediated cellular therapies. Reserve your seat now! ➡️ https://hubs.la/Q037501w0

We're excited to share the news of Indivumed Services' complete integration with Crown Bioscience. This strategic move, following the acquisition in 2023, solidifies our standing in oncology drug research and development. As a result of this merger, the Indivumed Services brand will be fully retired in February 2025. The merger unifies the strengths of both entities, offering pharmaceutical and biopharmaceutical partners a powerful toolkit of integrated platforms and services, including biospecimen solutions, to enhance the oncology drug development process from discovery through to clinical stages. Learn more ➡️ https://hubs.la/Q036TN5H0

In our new blog post, we detail the various ways in which data science is transforming oncology drug discovery. We provide you with highlights on key technologies, applications, and future directions, with a focus on detailed, scientific insights. The integration of data science and bioinformatics has become essential to modern oncology drug discovery. Researchers are now able to make better, more informed decisions, uncover hidden patterns in cancer biology, and streamline the development of life-saving therapies. Read or listen to the blog post ➡️ https://hubs.la/Q036DsFg0

Keeping your oncology drug development in one location is a complex priority, but it doesn’t need to be a complex journey. Protect your materials, studies, and relationships with a full suite of cutting-edge services at Crown Bioscience UK, together with our broader European operations. We remove the location and time zone hurdles so you can make faster, actionable, and more predictive decisions. Take the first step ➡️ https://hubs.la/Q036nXBK0

Earlier we shared news about our site in Germany having been awarded continued accreditation to the globally recognized ISO 15189:2022 standard by the College of American Pathologists (CAP). Simone Hubo, PhD, Director of Quality and Regulatory Affairs at Crown Bioscience Germany commented on this achievement. Read more about this achievement ➡️ https://hubs.la/Q036cJ5d0

📣We are proud to announce that our Hamburg site in Germany has been awarded continued accreditation to the globally recognized ISO 15189:2022 standard by the College of American Pathologists (CAP). This distinction underscores our unwavering dedication to quality and demonstrates technical excellence in laboratory services. The ISO 15189 standard provides laboratories with a rigorous framework for quality management, risk assessment, and continuous improvement. Accreditation is based on stringent requirements specific to medical laboratories. Our commitment to these standards affirms our focus on reducing risk and enhancing patient safety. Read more about this achievement ➡️ https://hubs.la/Q0369Gbp0 College of American Pathologists (CAP)

We’re excited to announce a special price discount on the NanoString nCounter® PanCancer IO 360™ Panel, available exclusively at our San Diego site. This limited-time promotion runs until March 31, 2025. The IO 360 Panel provides a 770-gene expression profile that captures key interactions between the tumor, microenvironment, and immune response, making it a valuable tool for checkpoint inhibitor research and immunotherapy response prediction. ✅Supports checkpoint inhibitor research & immunotherapy response prediction ✅Compatible with FFPE, fresh frozen, and cell lysate samples ✅Provides fast, reproducible results—no amplification required Learn more and request a quote: ➡️ https://hubs.la/Q035_Fqp0

Headquartered in California, US, we are a global contract research organization (CRO) providing discovery, preclinical and translational platforms and services to advance oncology and immuno-oncology. Our mission is to empower our customers to improve human health. We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation. Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time. Learn more about us ➡️ https://hubs.ly/Q034gTFS0

Organoids are revolutionizing in vitro modeling by providing 3D structures that closely mimic the architecture and function of human tissues. In this blog post, Crown Bioscience shares some of the key applications of organoids, such as developmental and stem cell biology, disease mechanisms, regenerative medicine & more. Read the full blog post, here: https://lnkd.in/gDUyKPXH